Results 31 to 40 of about 6,049 (169)

Comparison between febuxostat and allopurinol uric acid-lowering therapy in patients with chronic heart failure and hyperuricemia: a multicenter randomized controlled trial

Journal of International Medical Research, 2021
Objective Heart failure (HF) is a common and highly morbid cardiovascular disorder. Oxidative stress worsens HF, and uric acid (UA) is a useful oxidative stress marker.
Satoshi Suzuki, Akiomi Yoshihisa, Tetsuro Yokokawa, Atsushi Kobayashi, Takayoshi Yamaki, Hiroyuki Kunii, Kazuhiko Nakazato, Akihiro Tsuda, Tatsunori Tsuda, Toshiyuki Ishibashi, Ichiro Konno, Osamu Yamaguchi, Hirofumi Machii, Naoki Nozaki, Takeshi Niizeki, Takuya Miyamoto, Yasuchika Takeishi,   +17 more
doaj   +1 more source

The clinical pharmacokinetics and pharmacodynamics of febuxostat [PDF]

, 2018
Febuxostat lowers serum urate (SU) by inhibiting xanthine oxidoreductase. The data on the effect of renal function on the pharmacokinetics (PK) of febuxostat and the response of SU pharmacodynamics; PD) to febuxostat are limited and discordant ...
Kamel, Bishoy
core   +1 more source

Febuxostat ameliorates methotrexate-induced lung damage [PDF]

, 2021
Background: The intention of the present study was to assess the structural affection of the lung following methotrexate (MTX) overdose. The proposed underlying mechanisms involved in lung affection were studied.
Khalil, H. M.A.; Department of Veterinary Hygiene and Management, Faculty of Veterinary Medicine, Cairo University, Cairo, Egypt, Hussein, G. H.A.; Department of Anatomy and Embryology, Faculty of Medicine, Beni Suef University, Beni-Suef, Egypt, Abd Algaleel, W. A.; Department of Anatomy and Embryology, Faculty of Medicine, Cairo University, Cairo, Egypt, Zaki, S. M.; Fakeeh College for Medical Sciences, Jeddah, Saudi Arabia; Department of Anatomy and Embryology, Faculty of Medicine, Cairo University, Cairo, Egypt   +3 more
core   +1 more source

Cardiovascular safety associated with febuxostat versus allopurinol among patients with gout: Update with accumulated use of febuxostat

, 2022
Background: To re-evaluate comparative cardiovascular (CV) safety of febuxostat versus allopurinol among pa-tients with gout following recent accumulated use of febuxostat.Methods: Using 2011-2019 Korea National Health Insurance database, we conducted a ...
You-Jung Ha, Eun Bong Lee, Anna Shin, Yun Jong Lee, Se Rim Choi, Lee, Yun Jong, Lee, Eun Bong, Minji Han, Shin, Anna, Ha, You-Jung, Choi, Se Rim, Kang, Eun Ha, Han, Minji, Eun Ha Kang   +13 more
core   +1 more source

Ruthenium‐Catalyzed Nitrile‐Acrylate Reductive Coupling by 2‐Propanol: Synthesis of Enantioenriched β‐Amino Esters

Angewandte Chemie, EarlyView.
The first nitrile reductive couplings beyond stoichiometric metals or metalloids are described. Using a ruthenium catalyst derived from RuHCl(CO)(PPh3)3 and Cy‐BIPHEP, 2‐propanol‐mediated reductive coupling of phenyl acrylate with aromatic or aliphatic nitriles delivers α,β‐unsaturated β‐amino esters.
Sebastian Höthker, Colin E. Hayter, Weijia Shen, Michael J. Krische   +3 more
wiley   +2 more sources

Long-term inhibition of xanthine oxidase by febuxostat does not decrease blood pressure in deoxycorticosterone acetate (DOCA)-salt hypertensive rats. [PDF]

PLoS ONE, 2013
Xanthine oxidase and its products, uric acid and ROS, have been implicated in the pathogenesis of cardiovascular disease, such as hypertension.
Theodora Szasz, Robert Patrick Davis, Hannah S Garver, Robert J Burnett, Gregory D Fink, Stephanie W Watts   +5 more
doaj   +1 more source

Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial.

PLoS Medicine, 2020
BackgroundAn elevated level of serum uric acid (SUA) is associated with an increased risk of cardiovascular disease. Pharmacological intervention with urate-lowering agents, such as the conventional purine analogue xanthine oxidase (XO) inhibitor ...
Atsushi Tanaka, Isao Taguchi, Hiroki Teragawa, Nobukazu Ishizaka, Yumiko Kanzaki, Hirofumi Tomiyama, Masataka Sata, Akira Sezai, Kazuo Eguchi, Toru Kato, Shigeru Toyoda, Ryoichi Ishibashi, Kazuomi Kario, Tomoko Ishizu, Shinichiro Ueda, Koji Maemura, Yukihito Higashi, Hirotsugu Yamada, Mitsuru Ohishi, Kotaro Yokote, Toyoaki Murohara, Jun-Ichi Oyama, Koichi Node, PRIZE study investigators   +23 more
doaj   +1 more source

Febuxostat for Hyperuricemia in Patients with Advanced Chronic Kidney Disease

, 2014
Febuxostat is a nonpurine xanthine oxidase (XO) inhibitor, which recently received marketing approval. However, information regarding the experience with this agent among advanced chronic kidney disease (CKD) patients is limited. In the current study, we
Daisuke Nagata, Osamu Iimura, Tetsu Akimoto, Yuko Watanabe, Chiharu Ito, Eiji Kusano, Sadao Tsunematsu, Yoshiyuki Morishita   +7 more
core   +1 more source

Febuxostat and atrial fibrillation

, 2020
Recently there has been concern that febuxostat may be associated with increased cardiovascular risk than allopurinol,1 leading to a black-box warning by the Federal Drug Administration.
Borghi C, Kuwabara M, Johnson RJ
core   +1 more source

Nebenwirkungen und Interaktionen des Xanthinoxidasehemmers Febuxostat [PDF]

, 2017
Anzeichen für einen positiven Einfluss von Febuxostat auf die Aktivität der Xanthinoxidase in den Gefäßwänden und die Gefäßelastizität lassen eine Zunahme der Bedeutung dieses Medikaments erwarten.
Jordan, Andreas
core   +1 more source